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Elevated blood pressure predicts the risk of acute rejection in Acute rejection (AR) is a strong predictor of long term
renal allograft recipients. renal allograft survival [1–4]. Recent advances in immu-
Background. Acute rejection (AR) is a strong predictor of nosuppressive therapy have lowered the incidence ofrenal allograft survival. Recent advances in immunosuppres-
AR in renal transplant recipients considerably, but ARsion have reduced considerably the incidence of AR. Still, approx-
still occurs in approximately 25% of recipients [5, 6].imately 25% of patients have AR early post-transplant, and
the factors that predispose to AR have not been fully clarified. Aside from the type of immunosuppressive therapy, pre-
Methods. The study includes 1641 adults, recipients of first vious studies have identified several variables that are
cadaveric (CAD, N 5 1195) or living related renal grafts (LRD, associated with higher risk of AR, including: (1) youngN 5 446), transplanted in one institution. The variables associ-
recipients [7, 8]; (2) history of early failure of a previousated with the occurrence of AR during the first year post-
transplant [9]; (3) CAD kidneys [3, 10]; (4) lower HLAtransplant were identified.
Results. By univariate analyses, AR was associated with the matching (for example [8]); and (5) African American
following variables: younger (P , 0.001); heavier (P 5 0.003); race [11]. Still, the identification of patients at high risk
and African American recipients (P 5 0.002); CAD transplants
for AR remains unreliable. However, this determination(P 5 0.001); higher number of HLA mismatches (P 5 0.001);
could be quite beneficial because it may be used to de-delayed graft function (DGF, P 5 0.001); higher levels of serum
creatinine post-transplant (P 5 0.003); and higher levels of velop risk adjusted immunosuppression strategies. In ad-
systolic and/or diastolic blood pressure (BP) post-transplant dition, the search for variables associated with risk of
(P , 0.001). Higher BP levels were also associated with earlier AR may disclose new factors that may be amenable to
AR episodes (P , 0.0001). By multivariable analysis AR was
prophylaxis and/or therapy.significantly associated with recipient age, number of HLA
Previous studies indicated that donor factors also cor-mismatches, DGF, pre-PRA and systolic BP. Analysis of BP
measured weekly post-transplant indicated that elevated BP relate with risk of AR [12]. This association may be ex-
levels, even three weeks prior to the AR episode, were signifi- plained at least in part by the experimental observation
cantly associated with AR. For every level of BP, the use of that ischemic renal injury predisposes to AR [3, 10]. In
BP medications was associated with a lower incidence of AR
humans, delayed graft function (DGF), likely a reflection(P , 0.0001). Furthermore, the use of calcium channel blockers
of ischemic damage, is also associated with increasedwas also associated with lower incidence of AR (P 5 0.001).
Of note, 81% of recipients whose BP increased after the trans- AR risk [13–16]. In these studies we sought to determine
plant had AR. In contrast, 22% of patients whose BP declined whether BP levels post-transplant correlate with the inci-
post-transplant had AR. dence of AR. The rationale for this aim is the recent
Conclusions. Elevated BP levels post-transplant identify pa-
observation that patients with AR have significantlytients at high risk of AR independently of graft function. Treat-
higher BP than patients without AR [17]. Furthermore,ment of BP and reduction of BP levels appears to be associated
with a decreased risk of AR. We hypothesize that high BP it is reasonable to postulate that damage to the donor
may be an indicator of a particular type of allograft damage, kidney, that increases the risk for AR, may cause hyper-
perhaps ischemic, that may predispose to AR. tension in the recipient. For these studies we selected
patients who either had no AR or had their first AR
episode during the first year post-transplant. PatientsKey words: renal transplantation, blood pressure, BP medications, cal-
cium channel blockers who had their first AR episode later than one year post-
transplant were excluded because other factors, such asReceived for publication February 1, 1999
compliance with medications, are likely to play a majorand in revised form August 9, 2000
Accepted for publication September 28, 2000 role in the pathogenesis of those later AR episodes. These
analyses identified expected and unexpected variablesÓ 2001 by the International Society of Nephrology
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that correlate with the incidence of AR in renal trans- sion. Post-transplant, 92% of patients received induction
immunosuppression consisting of polyclonal (Minnesotaplant recipients, and suggest therapeutic approaches that
may be effective adjuncts to the prevention of AR. ALG or ATG) or monoclonal antilymphocyte antibodies
(OKT3, Ortho Biotech, Raritan, NJ, USA) until the serum
creatinine was #2.5 mg/dL when cyclosporine (CsA) was
METHODS
initiated. Maintenance immunosuppression consisted of
Study population triple therapy with prednisone, azathioprine and CsA
until mid 1995, when azathioprine was replaced by myco-The patient population included all adult patients who
received their first renal transplant at The Ohio State phenolate mofetil (CellCept) at a dose of 2 to 3 g/day.
CsA levels were not collected in a systematic fashion inUniversity from 9/26/82 to 6/14/96 (N 5 1641). Among
these patients 446 received kidneys from living related all patients and consequently those values could not be
analyzed in this study.donors (LRD) and 1195 from cadaveric donors (CAD).
Eight hundred ninety-three patients (54%) had no AR
Analysis of the datathroughout the transplant course and 748 (46%) had AR
during the first year post-transplant. Values throughout the manuscript are expressed as
mean 6 standard deviation of the mean. Mean valuesIn patients with AR, clinical variables were collected
prior to the occurrence of the AR episode. For compari- were compared through the use of the Student’s t-test
or by a Wilcoxon Rank Sum test if the variable underson, in patients without AR post-transplant variables
were collected during the first three months post-trans- consideration was not normally distributed. Proportions
were compared using Chi-square tests or Fisher’s Exactplant. This time interval was selected because the large
majority of first AR episodes (86.4%) occurred during test when cell frequencies were small. Multivariable asso-
ciations between the occurrence of AR and groups ofthis period of time. Among the clinical variables that
we evaluated the following require clarification. (1) The independent variables were assessed through the use
of logistic regression analysis. Goodness-of-fit tests andpre-AR serum creatinine concentration (pre-Cr) was
considered to be the lowest creatinine during the month area-under-the-receiver operating characteristic curve
were used as measures of model performance. The rela-prior to the diagnosis of AR. In patients without AR,
pre-Cr was the lowest creatinine during the first three tionship between weekly post-transplant BP and AR was
analyzed using Cox regression with the BP value as amonths post-transplant. (2) The pre-AR BP (pre-BP)
was analyzed two ways: In the initial studies pre-BP time dependent covariate. Risk of AR during a particular
week post-transplant was modeled using blood pressurewas the average systolic (SBP), diastolic (DBP) or mean
arterial pressure (MAP) from the time of transplantation values from that same week as well as from the prior
one, two or three weeks. This analysis was limited to ato the time of diagnosis of AR. For comparison, in pa-
tients without AR, the pre-BP was the average BP during lag of three weeks since most AR episodes occur during
the first month post-transplant. Thus, an analysis of BPthe first three months post-transplant. In a second analy-
sis, post-transplant BP, in patients with or without AR, more than three weeks prior to the week under evalua-
tion would have excluded the majority of patients withwas analyzed weekly and that value represented the aver-
age of all BP recording for each week post-transplant. AR. The validity of the proportional hazards assumption
was assessed through the significance of the interactionBP values included recordings done by the patient at
home and called to our post-transplant office, and re- term between the covariate under consideration and the
log of time.cordings obtained during outpatient clinic visits. A total
of 69,622 BP readings were analyzed at an average of
36.6 readings per patient among recipients without AR
RESULTS
and 39.3 determinations per patient among those with
Patient characteristicsAR. (3) For these studies, BP medications were classified
as: diuretics, calcium channel blockers (CCB); peripheral Table 1 presents characteristics of the donor and the
recipient population. Among the 1641 patients, 893 (54%)vasodilators; beta blockers; alpha blockers; and angio-
tensin converting enzyme inhibitors. (4) Values for BP had no AR episodes during the first year post-transplant.
Of those patients with an AR episode, 86% occurredprior to the transplant were obtained in 337 CAD recipi-
ents by review of pre-transplant evaluation, dialysis re- within the first three months post-transplant.
cords, and outpatient clinic visits. (5) AR was diagnosed
Univariable relationships with occurrence of ARbased on clinical information and in 82% of the cases
also by biopsy [18, 19]. (6) Delayed graft function (DGF) Table 2 presents the results from univariable compari-
sons between those subjects with and without an ARpost-transplant was defined as the need for dialysis dur-
ing the initial transplant hospitalization. episode in the first year post-transplant. For these analy-
ses, patients who did not experience an AR episode butAll CAD kidneys were preserved by pulsatile perfu-
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Table 1. Characteristics of the patient population (N 5 1641)
Variable Na Value
Donor age years 1182 33.2615.5
Donor race % Caucasian 1036 86.5%
Donor gender % males 939 57.6%
Donor origin % CAD 1195 72.8%
Recipient age years 1640 42.06 14.6
Recipient race % Caucasian 1282 80.2%
Recipient gender % males 939 58.8%
Recipient weight in kg 1191 74.16 20.5
Preservation time CAD, in hours 1060 14.36 13.7
HLA mismatches A1B1D 1479 4.16 1.7
Peak PRA 1336 5.5615.2
DGF % of patients 112 7.0%
Pre-Cr mg/dL 1619 1.86 1.2
Pre-systolic BP mm Hg 1548 141.9615.9
Pre-diastolic BP mm Hg 1548 82.56 9.1
Pre-MAP mm Hg 1548 102.469.8
Acute rejection % of patients 1641 45.6% Fig. 1. Percent of patients with acute rejection, AR (y axis) according
Acute rejection first 3 months % of AR 646 86.4 to average pre-systolic blood pressure (SBP) levels (x axis). The number
of patients in each group is: ,130, N 5 126; 130–140, N 5 256; 140–150,Abbreviations are: CAD, cadaveric graft recipient; PRA, panel reactive anti-
N 5 344; 150–160, N 5 383; .150, N 5 439.bodies; DGF, delayed graft function; Cr, creatinine; BP, blood pressure; MAP,
mean arterial pressure; AR, acute rejection.
a Number of observations
to these observations, the following parameters were
not significantly different between patients with AR andTable 2. Testing for associations between AR and
recipient/donor characteristics those without: donor age, race or gender; PRA levels;
and recipient gender. In addition, there were no signifi-Mean6SD
cant differences in the doses of immunosuppressive med-
Variable AR No AR P value
ications in patients with or without AR. For example,
Recipient age years 40.2613.8 43.2615.1 ,0.001a during the first three months post-transplant patientsHLA mismatches A1B1D 4.361.6 3.861.8 ,0.001b
without AR received 863 6 613 mg/kg of CsA and 3.2 6Pre-CR mg/dL 1.861.2 1.660.5 0.003a
Pre-BP systolic mm Hg 149.0614.5 135.3613.9 ,0.001a 2.2 g of prednisone, while patients with AR received
Pre-BP diastolic mm Hg 86.068.5 79.668.2 ,0.001a
783 6 538 mg/kg of CsA and 3.5 6 2.4 g of prednisone.Pre-BP MAP 107.168.9 98.268.4 ,0.001a
Weight kg 75.3620.0 71.5621.1 0.003b The relationship between SBP and AR is displayed
graphically in Figure 1. As can be seen, increasing levelsN (%)
of SBP were associated with progressive increases in theVariable AR No AR P value
incidence of AR (P , 0.0001, logistic regression). The
Donor origin
level of SBP also correlated with the time of the ARCAD 575 (52.2) 527 (47.8) 0.001c
LRD 173 (41.1) 248 (58.9) episode such that higher levels of SBP correlated with
Recipient race earlier AR episodes (r 5 20.227, P , 0.0001, SpearmanCaucasian 585 (48.9) 612 (51.1) 0.002c
rank; Fig. 2).African American 157 (58.6) 111 (41.4)
Other 6 (28.6) 15 (71.4)
DGF Multivariable relationships with occurrence of AR
No 687 (48.9) 717 (51.1) 0.001c using Logistic regressionYes 61 (74.4) 21 (25.6)
Table 3 presents the results of a model building activitya P value obtained using Student t test
b P value obtained using Wilcoxon rank sum test to determine the set of patient/donor characteristics as-
c P value obtained from Chi-square test
sociated with the occurrence of an AR episode. As in
the univariable analyses, patients who did not experience
an AR episode but were not followed for the complete
first year were excluded from the analysis. As can bewere not followed for the complete year were excluded.
seen, the age of the recipient, the number of HLA mis-As can be seen, patients with an AR were significantly
matches, pre-PRA, pre-SBP, kidney function post-trans-younger; had more HLA mismatches; had higher creati-
plant and gender of the recipient were found to be sig-nine levels before the AR; had higher systolic, diastolic,
nificantly related to AR. Patients over the age of 25and mean arterial blood pressure; and were heavier. Fur-
were 67% less likely to experience an AR than youngerthermore, patients who had received a CAD transplant;
recipients. The risk of AR increases by more than four-patients with DGF; and African American recipients
were also more likely to have an AR episode. In contrast fold for every 20 mm Hg increase in SBP. Male recipients
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Table 4. Results from multivariable Cox regression analyses,
total sample (N 5 1197)
Variable Risk ratio 95% CI
SBP 1.39a 1.26a, 1.52a
Donor type
CAD 2.14b 1.60b, 2.87b
LRD — —
Age 0.84c 0.79c, 0.89c
Pre-PRA 1.20b,c 1.08b,c, 1.34b,c
HLA mismatches 1.10 1.04, 1.17
DGF 1.66 1.23, 2.24
Pre-Cr 3.52b 0.92b, 13.51b
Weight 1.05c 1.01c, 1.10c
a Based on a 20 mm Hg change
b Calculated at 180 days post-transplant
c Based on a 10 unit change
Fig. 2. Relationship between pre-SBP levels and the time of the first
AR episode. Increasing pre-SBP are associated with earlier AR (r 5
When a model was fit only with recipients of CAD20.227, P , 0.0001).
kidneys or only with recipients of LRD kidneys the re-
sults of the analysis were similar. That is, the variables
displayed in Table 3 correlated with AR in CAD and inTable 3. Results from multivariable Logistic regression analyses
(N 5 1641) LRD recipients (data not shown).
Variable 6X se(6X) aORa 95% CI
Multivariable relationships with occurrence of AR
Recipient age using Cox regression,25 years — — — —
.25 years 21.11 0.212 0.33 0.22,0.50 A multivariable model to determine the time until AR
HLA mismatch 0.122 0.044 1.13 1.04,1.23 event was constructed using the patient/donor character-Pre-PRA 0.011 0.005 1.12b 1.02b, 1.23b
istics given in Tables 1 and 2. However, in this model,Pre-SBP 0.072 0.006 4.24c 3.41c, 5.26c
DGF SBP was treated as a time-dependent covariate, thus
Yes 0.634 0.297 1.89 1.05,3.37 allowing for the risk of an event to change as the patients’No — — — —
SBP changed. The SBP values used in the analysis wereRecipient sex
Male 20.239 0.139 0.79 0.60,1.03 the weekly averages for each patient. In this analysis it
Female — — — — was not necessary to exclude those patients who did notModel analysis
experience an event but with observation times less thanIntercept 29.770 0.771
Sample size 1146 one year. Results are presented in Table 4. As in the
Area under ROC curve 0.797 logistic regression models, SBP was significantly relatedGoodness of fit
to the AR event. A 20-unit increase in SBP correspondsChi-square 9.616
P value 0.293 to a 39% increase in the risk of an AR episode. In this
a aOR, stimulated odds ratio model, donor type was also related to risk of an AR
b Based on a 10 unit change event although the risk was not constant across timec Based on a 20 unit change
(that is, the proportional hazards assumption was not
satisfied). Thus, early after transplantation, LRD recipi-
ents are at higher risk of an AR episode, but as timewere 20% less likely to experience an AR episode. Pa-
progresses the risk becomes greater for those patientstients whose kidneys did not begin to function soon after
receiving cadaveric transplants. For example, by day 180,transplant were almost twice as likely to have an AR
a CAD recipient is 2.14 times more likely to experience anepisode. Interestingly, donor type (CAD or LRD) was
AR episode than an LRD recipient. However, this risknot significantly related to AR in the final model, al-
would be different had a different reference day beenthough it was related in the univariable comparisons.
chosen. As in the Logistic regression analysis, increasingThe Chi-square value (x2 5 9.616; Table 3) and corre-
age is associated with a lower risk of AR while increasingsponding P value (P 5 0.293) for the goodness-of-fit
pre PRA, number of HLA mismatches, pre-Cr, andstatistic suggest that the model provides accurate esti-
weight correspond to an increase risk of an AR episode.mates of the probability of an AR event (that is, the
As with donor type, the risk of AR is not constant acrossmodel demonstrates good calibration). The model’s good
time for pre-PRA and pre-Cr. Patients with DGF haveperformance is also shown by the high degree of discrimi-
a 66% increased risk of AR.nation as measured by the area under the ROC curve
(area 5 0.797). In additional analyses, the risk of an AR event was
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modeled as a function of the SBP values one, two or
three weeks prior to the actual week of the AR. In each
of these models, SBP was again significantly associated
with the risk of an AR episode (P 5 0.001 at a one-
week lag, P 5 0.001 at a two week lag, and P 5 0.03
at a three-week lag). Thus, the risk of AR is not only
associated with the SBP value in a given week but also
with SBP values for at least the three weeks prior to the
event.
It should be noted that there were some differences
between the results shown in Table 3 and Table 4 that
may be due to differences in statistical methodology and
in the number of patients in each analysis. However, in
both analyses, it is clear that SBP is a significant predictor
of an AR event and that the risk of AR increases with
increasing SBP.
Effects of BP treatment on the relationship between
BP and AR
During the first month post-transplant 89.9% or pa-
tients without AR and 70.3% of patients with AR re-
ceived BP medications (P 5 0.001). Thereafter, the per-
cent of patients receiving BP medications were not
significantly different between both groups of patients.
The types of BP medication were also similar between
patients with AR and those without with the exception
that during the second month post-transplant, 42.6%
of patients with AR and 34% of patients without AR
received CCB (91% dihydropyridines; P 5 0.01).
Of interest, patients who received BP medications had
a significantly lower incidence of AR than patients who
did not receive those medications (P , 0.0001, Logistic
Fig. 3. (A) Correlation between blood pressure (BP) treatment andregression). Furthermore, as displayed in Figure 3A the
the incidence of AR in patients classified according to pre-SBP levels.effect of BP treatment was significant for each level of
The numbers of patients in each group are as follows: no treatment
achieved BP. Among patients treated with BP medica- ( ), SBP ,130, N 5 48; SBP 130–145, N 5 44; SBP . 145, N 5 90;
treatment (j), SBP , 130, N 5 334; SBP 130–145, N 5 495; SBP . 145,tions the incidence of AR was significantly lower in pa-
N 5 536. (B) Incidence of AR in patients who received BP medicationstients treated with CCB (Fig. 3B; P 5 0.001, Logistic
classified according to whether or not they received CCB. The numbers
regression). None of the other classes of BP medications of patients in each group are as follows: no CCB (j), SBP , 130, N 5
196; SBP 130–145, N 5 267; SBP . 145, N 5 276; CCB ( ), SBP ,correlated significantly with the incidence of AR.
130, N 5 138; SBP 130–145, N 5 228; SBP . 145, N 5 260.
Correlations between BP post-transplant and
other variables
Higher pre-BP levels correlated with (1) increasing SBP pre-transplant but “high” SBP (.150 mm Hg) post-
transplant (N 5 45); (3) patients with high SBP beforedonor age; (2) recipients of CAD grafts; (3) elevated BP
prior to the transplant; (4) recipients who were male, but not after the transplant (N 5 108); and (4) patients
with “high” SBP before and after the transplant (N 5overweight, African American, and/or older; and (5) in-
creasing serum creatinine post-transplant (P # 0.001 for 61). As can be seen in Figure 4, the incidence of AR
is highest in patients with elevated BP post-transplantall correlations by Pearson or Spearman rank). Of all
of these variables, the recipient’s weight and the pre- irrespective of their BP level pre-transplant. Further-
more, it is of interest to note that the highest incidencetransplant BP were statistically the strongest predictors
of BP post-transplant. of AR (81% of patients) occurred in patients whose SBP
increased from “low” to “high” following transplanta-We next analyzed the incidence of AR in patients
classified in the following groups: (1) patients with “low” tion. In contrast, the lowest incidence of AR (22% of
patients) was among patients with lower BP post-trans-SBP (defined arbitrarily as ,150 mm Hg) before and
after transplantation (N 5 123); (2) patients with “low” plant than pre-transplant. Serum creatine concentrations
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transplant BP levels was also shown in previous studies
[20] and raises the question of whether the level of BP
pre-transplant can be used to predict the risk of AR. This
study showed that the post-transplant BP level correlates
better with the risk of AR than the pre-transplant BP. We
believe this particular finding provides the most telling
evidence for the role of the donor graft as a determinant
of BP post-transplant, and as a risk factor for AR. Thus,
patients who had a significant rise in BP following the
transplant also had a high risk for AR. In contrast, pa-
tients who had a significant reduction in BP level post-
transplant had a low risk of AR.
Although the previous arguments support the role of
the graft in BP control, they do not explain why patients
with higher BP post-transplant have a higher risk of AR.
Two non-mutually exclusive postulates can be offered to
explain this relationship: (1) the conditions of the do-
nor organ that cause elevated BP levels also predisposeFig. 4. Incidence of AR in patients classified according to SBP levels
prior to the transplant and after the transplant. “Low” was arbitrarily to AR; and/or (2) high levels of BP in the recipient pre-
defined as a SBP , 150 mm Hg and “high” as a SBP . 150 mm Hg. dispose to AR. Regarding the first postulate, graft vascu-
lar damage resulting from ischemia could explain both
an elevation of BP levels and a higher incidence of AR.
Thus, it has been reported that in experimental animals,were not significantly different among these four groups
ischemia induces phenotypic changes in the graft thatof patients (data not shown).
predisposes to AR [3, 10]. Similarly, in humans, DGF,
a manifestation of ischemia/reperfusion injury, is associ-
DISCUSSION ated with an increased risk of AR [13, 15]. It should be
The results of these studies indicate that the level of noted, however, that the experimental studies mentioned
BP post-transplant can be used to identify patients with previously evaluated the effects of acute ischemia/reper-
high or low risk of AR during the first year of transplanta- fusion on the graft and at least some of those effects are
tion. Furthermore, patients with elevated BP levels are known to be transient. Whether the phenotypic changes
also more likely to have AR earlier post-transplant. Of that appear to predispose to AR persist on a graft that
importance, these analyses also showed that the relation- is chronically ischemic is unknown. Of interest, recent
ship between BP and the incidence of AR is independent studies identified ischemia/reperfusion injury of the graft
of other variables that correlate with AR and/or BP, as a risk factor for elevated BP levels one year post-
including: origin of the graft, recipient race, doses of transplant [21]. We cannot exclude the postulate that
immunosuppressants, and graft function. Analysis of high BP may have a pathogenic role in the development
weekly post-transplant BP indicated that the higher lev- of AR. However, to our knowledge there is no evidence
els of BP precede the AR episode by at least three weeks, of a pathogenic link between hypertension and AR.
indicating that BP is a predictor of AR and that this Whether BP levels reflect graft damage and/or play a
correlation is not due to an effect of AR on BP. role in the pathogenesis of AR these observations raise
These results are consistent with the postulate that the possibility that BP control may help prevent AR. In
the donor organ is a major determinant of the BP level fact, we showed here that for the same level of BP, patients
in the recipient during the early post-transplant period. who received BP medications were at a lower risk of AR
Several observations support this postulate, including than untreated patients. Furthermore, the reduction in
the correlations noted here between higher BP levels the incidence of AR among patients who received BP
and CAD recipients, older donors, and in the presence medications correlates with both the level of BP and the
of an elevated serum creatinine concentration. Further- use of CCB. Several previous studies suggested the CCB-
more, in previous studies we showed a significant correla- treated patients have a significant reduction in the inci-
tion between the post-transplant BP levels of patients dence of AR [22–24]. However, these studies generally
who received grafts from the same donor [12]. In addition included small numbers of patients, did not control for
to donor variables, several recipient factors correlate BP levels and were retrospective. Theoretically, CCB
with BP levels post-transplant, including weight, race, could affect the incidence of AR by several mechanisms,
gender, age and, most importantly, the BP level prior to including changes in the metabolism of CsA, ameliora-
tion of ischemia/reperfusion damage, and also perhapsthe transplant. The correlation between pre- and post-
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rejection episodes with complete functional recovery. Transplanta-intrinsic immunosuppressive effects of these drugs [re-
tion 63:1739–1743, 1997
viewed in 24]. In this study, the lower incidence of AR 9. Kincaid-Smith P, Morris PJ, Saker BM, et al: Immediate renal-
graft biopsy and subsequent rejection. Lancet 748–749, 1968in CCB treated patients cannot be attributed to changes
10. Ojo AO, Port FK, Mauger EA, et al: Relative impact of donorin the metabolism of CsA because most of the patients
type on renal allograft survival in black and white recipients. Am
received dihydropyridines, a class of CCB that does not J Kidney Dis 25:623–628, 1995
11. Neylan JF: Immunosuppressive therapy in high-risk transplantalter the metabolism of CsA.
patients. Transplantation 64:1277–1282, 1997Studies done in the last few years showed that systemic
12. Cosio FG, Qiu W, Henry ML, et al: Factors related to the donor
hypertension is an important determinant of graft and organ are major determinants of renal allograft function and sur-
vival. Transplantation 62:1571–1576, 1996patient survival after renal transplantation [2, 17, 25–27].
13. Shoskes DA, Cecka JM: Deleterious effects of delayed graft func-The present results add a new potential pathogenic role
tion in cadaveric renal transplant recipients independent of acute
of hypertension on renal allografts. Because better BP rejection. Transplantation 66:1697–1701, 1998
14. Marcen R, Orofino L, Pascual J, et al: Delayed graft functioncontrol may provide an opportunity to improve the prog-
does not reduce the survival of renal transplant allografts. Trans-nosis of renal transplant recipients, prospective studies
plantation 66:461–466, 1998
designed to test the role of BP control and the level of 15. Tilney NL, Guttmann RD: Effects of initial ischemia/reperfusion
injury on the transplanted kidney. Transplantation 64:945–947,BP control on AR prevention, graft and patient survival
1997are needed.
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